BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, February 13, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 1, 1998

View Archived Issues

Results published from phase II trial of Immune Response's rheumatoid arthritis treatment

Read More

First patient treated in phase II HIV gene therapy study

Read More

Abbott purchases additional La Jolla stock

Read More

AngioMARK significantly improves imaging of vascular structures in phase II trial

Read More

Jenner Biotherapies receives patent on improved vaccine formulation

Read More

SB launches smoking cessation line in European markets

Read More

Naphthylpiperazine antipsychotics synthesized at Faes

Read More

Pfizer claims new series for BPH with selective prostatic alpha1-adrenoceptor-antagonist effects

Read More

Orion launches entacapone in first markets and updates safety information

Read More

Lilly describes use of dihydrobenzo[b]indenothiophenes for estrogen-related pathologies

Read More

Piperidine derivatives from Sanofi useful for neurokinin-dependent pathologies

Read More

New antiparasitic agents in development at Bayer

Read More

FDA completes review of BioTime's NDA for Hextend

Read More

Dual ACE/NEP inhibitor compared to ACE inhibitor for efficacy in hypertension

Read More

Tamsulosin improves signs and symptoms of BPH in phase III study

Read More

ABS receives funding from NIH to support development of Alzheimer's drug

Read More

AN-9 compared to butyric acid and paclitaxel against primary human tumor colony-forming units

Read More

Preclinical studies of XV-454 support further testing of novel fibrinogen antagonist

Read More

Combretastatin preclinical studies demonstrate antitumor efficacy when combined with radiation

Read More

Dual 5-LO/COX inhibitor from Eisai displays potent antiinflammatory efficacy in vivo

Read More

FDA informs Ligand that Panretin Gel is approvable

Read More

SB submits novel type II diabetes Rx for FDA approval

Read More

Phase II prostate cancer trial of Atragen now in progress

Read More

One Alkermes-R.W. Johnson collaboration makes progress, while another is terminated

Read More

AMBI seeks partners to develop oral nisin for colon infections

Read More

Another market introduction for Lilly's SERM for postmenopausal women

Read More

Asthma program accelerated by Genome Therapeutics and Schering-Plough

Read More

Chiron completes sale of diagnostics business to Bayer

Read More

Vical reports delivery of cytokine and antitumor activity using naked DNA gene transfer

Read More

Late-breaking news: Hoechst and Rhone-Poulenc announce creation of Aventis

Read More

Popular Stories

  • Today's news in brief

    BioWorld
  • Illustration of SCAN in Parkinson’s vs healthy subcortex

    SCAN is core circuit affected in Parkinson’s disease

    BioWorld Science
    Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
  • Woman and 3D brain

    Astellas’ ASP-2246 shows promise in stroke management

    BioWorld Science
    Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
  • 3D illustration of skin layers

    TL1A is overexpressed in hidradenitis suppurativa

    BioWorld Science
    Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for Feb. 10, 2026
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing